Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy.
The present prospective study intends to evaluate health-related quality of life (HRQL) and cognitive functioning in adult patients with supratentorial World Health Organization (WHO) grade II glioma (LGG) prior to observation/therapy and to determine possible influences of tumor-related factors on these measures. Adult patients with biopsy-proven supratentorial LGG were considered eligible (study period 18 months). Besides detailed documentation of patient clinical status we evaluated HRQL using the Short Form-36 (SF-36) Health Survey and applied the Beck Depression Inventory. Furthermore, attention and verbal memory functions were tested. Data from matched healthy control populations served as reference, and T-values were compared using Mann-Whitney U tests. For correlation of scores the Pearson test was utilized. Thirty-three patients with median Karnofsky Performance Status (KPS) of 80 were evaluated. Selective and divided attention showed significant impairment (P < 0.005), while verbal memory functions were unaffected. HRQL evaluated by SF-36 Health Survey was significantly reduced predominantly in the psychological domains (P < 0.025 to P < 0.0005). Nine patients displayed mild to moderate depression. Duration of symptoms >20 weeks and presence of seizures negatively affected aspects of HRQL, while cognitive functions were not influenced. KPS <80 correlated significant only with reduced physical functioning (P < 0.002) and role functioning (P < 0.01) on the SF-36 Health Survey. While displaying good clinical status, patients with LGG showed significant impairment in aspects of attention and affections of HRQL already at time of diagnosis. These results suggest that these impairments originate from the tumor and/or potentially from confrontation with the diagnosis itself.
Ruge
Maximilian I
MI
Department of Stereotactic and Functional Neurosurgery, University Clinics of Cologne, Cologne, North Rhine-Westphalia, Germany.
Ilmberger
Josef
J
Tonn
Jörg-Christian
JC
Kreth
Friedrich-Wilhelm
FW
D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000209:etiology / Q000523:psychology*; D005260:Female; D005910:Glioma / Q000150:complications / Q000523:psychology* / Q000628:therapy; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009483:Neuropsychological Tests; D010865:Pilot Projects; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D015173:Supratentorial Neoplasms / Q000150:complications / Q000523:psychology* / Q000628:therapy; D014944:World Health Organization; D055815:Young Adult
Cancer. 1997 Jan 15;79(2):370-9
9010111
J Neurooncol. 2007 Jan;81(2):175-84
16850104
J Neurooncol. 2009 May;92(3):253-9
19357953
Ann Neurol. 2003 Oct;54(4):514-20
14520665
Neurology. 2000 Apr 11;54(7):1442-8
10751254
Soc Sci Med. 1995 Nov;41(10):1359-66
8560303
J Clin Oncol. 2009 Aug 1;27(22):3712-22
19470928
Neurosurgery. 1992 Oct;31(4):636-42; discussion 642
1407448
Neurology. 2001 Mar 13;56(5):618-23
11245713
J Neurol. 2002 Aug;249(8):955-60
12195437
Lancet Neurol. 2004 Mar;3(3):159-68
14980531
Eur J Cancer. 2010 Apr;46(6):1033-40
20181476
J Neurol Neurosurg Psychiatry. 1992 May;55(5):372-6
1602310
J Clin Oncol. 2000 Sep 15;18(18):3295-301
10986063
Lancet Neurol. 2009 Sep;8(9):810-8
19665931
Ann Neurol. 1994 Jul;36(1):48-54
8024261
Eur J Cancer. 1998 Nov;34(12):1902-9
10023313
Lancet. 2002 Nov 2;360(9343):1361-8
12423981
J Neurooncol. 2008 Feb;86(3):321-7
17926007